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Abstract
Polymeric microparticles have been used widely for sustained drug delivery. Current methods of
microparticle production can be improved by making homogeneous particles in size and shape,
increasing the drug loading, and controlling the initial burst release. In the current study, the
hydrogel template method was used to produce homogeneous poly(lactide-co-glycolide) (PLGA)
microparticles and to examine formulation and process-related parameters. Poly(vinyl alcohol)
(PVA) was used to make hydrogel templates. The parameters examined include PVA molecular
weight, type of PLGA (as characterized by lactide content, inherent viscosity), polymer
concentration, drug concentration and composition of solvent system. Three model compounds
studied were risperidone, methylprednisolone acetate and paclitaxel. The ability of the hydrogel
template method to produce microparticles with good conformity to template was dependent on
molecular weight of PVA and viscosity of the PLGA solution. Drug loading and encapsulation
efficiency were found to be influenced by PLGA lactide content, polymer concentration and
composition of the solvent system. The drug loading and encapsulation efficiency were 28.7% and
82% for risperidone, 31.5% and 90% for methylprednisolone acetate, and 32.2 % and 92 % for
paclitaxel, respectively. For all three drugs, release was sustained for weeks, and the in vitro
release profile of risperidone was comparable to that of microparticles prepared using the
conventional emulsion method. The hydrogel template method provides a new approach of
manipulating microparticles.
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1. Introduction
Polymeric microparticle drug delivery systems have been widely explored for controlled
delivery of active pharmaceutical ingredients. Microparticles provide several advantages as
drug delivery vehicles, such as protection of encapsulated drug from unfavorable
environmental conditions and ability to control drug release profile for a specified period of
time (1). In particular, the potential to control drug release profile over an extended period of
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time is one of the most desirable attributes (2). Suitable drug candidates that may benefit
greatly from such controlled drug delivery systems based on polymeric microparticles
include those that have a broad therapeutic window, require a low daily dose and are used
for the long-term treatment of disease.
Poly(lactide-co-glycolide) (PLGA) is probably the most extensively used polymer in
microparticle drug delivery systems (1). This copolymer of lactide and glycolide degrade by
simple hydrolysis when exposed to an aqueous environment such as inside the human body.
PLGA has been used in a host of drug products approved by Food and Drug Administration
(FDA), such as Zoladex Depot® (goserelin), Lurpon Depot® (leuprolide), Sandostatin
LAR® Depot (octreotide acetate), Nutropin Depot® (somatotropin), Trelstar® (triptorelin),
Somatulin® Depot (lanreotide), Risperidal® Consta® (risperidone), Vivitrol® (naltrxone)
and Bydureon® (exenatide). PLGAs are available at various molecular weights (or intrinsic
viscosities) and lactide/glycolide ratios with either ester end-caps or free carboxylic acid
end-caps. The properties of PLGA have been shown to influence important microparticle
characteristics, such as the amount of drug loading, loading efficiency and drug release both
in vitro and in vivo (3–5). Previous studies have demonstrated that the rate of hydrolysis, and
therefore, drug release is heavily dependent on the PLGA molecular weight and monomer
composition. Consequently, it is possible to design PLGA-based microparticle drug delivery
systems with tailored polymer degradation characteristics and release patterns by varying the
PLGA composition.
In addition to polymer composition and properties, there are other formulation- and process-
related parameters that may affect microparticle performance. Formulation-related factors
include type of organic solvent used, concentration of polymer used, and drug-polymer
interactions (3, 6, 7). Various studies have shown that these formulation-related factors
affect drug encapsulation efficiency and drug distribution within polymeric matrix, which in
turn influences the initial burst release. The initial burst release is one of the major
challenges in developing drug-encapsulated microparticle systems. The release of a large
bolus of drugs before microparticles reach a steady state release is both therapeutically
undesirable and economically ineffective. Therefore, the ability to control and limit the
initial burst release is highly sought-after and extensively studied. In addition, there are
process-related parameters that can affect the performance of microparticles produced using
these methods. Currently, spray drying and emulsion-based methods are well-established
and most commonly used to prepare drug-loaded PLGA microparticles. Process-related
parameters in these methods that influence drug-loaded microparticle characteristics include
the ratio of dispersed phase to continuous phase and the rate of solvent removal/extraction.
The factors outlined above and their effects on microparticle performance, however, have
been mostly studied in the emulsion-based methods only.
Although emulsion-based and spray-drying methods are widely used, their applicability is
restricted by a number of limitations. Techniques such as spray drying may be unsuitable for
substances sensitive to heating and mechanical shear of atomization, which narrows the field
of applicability for this technique (8). Low product yield due to deposition of materials on
the interior surface of drying chamber is yet another common concern for spray drying. For
both spray drying and emulsion-based methods particle formation is random and results in
microparticles with broad size distribution (9). Microparticle size is an important factor that
affects the choice of administration route (10–12), drug encapsulation within the
microparticle and therefore drug release profile from the delivery vehicle (13–15). Another
common problem with spray drying and emulsion-based methods is low drug loading, often
with an average of less than 10% (16–18). Certainly there is room for improvement in
microencapsulation techniques.
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To address limitations associated with conventional methods of microparticle preparation,
we have developed a microfabrication technique for preparation of microparticles. The
approach utilizes the unique properties of physical gels that can undergo sol-gel phase
transitions or water-soluble polymers that do not dissolve in organic solvents. The approach
is collectively called the hydrogel template method (19). The hydrogel template approach
allows a more precise control of microparticle size and shape, which translates into narrow
size distribution and increased microparticle homogeneity. In addition, the method provides
flexibility in producing microparticles of various desirable size ranges. Another
improvement over existing methods is the possibility of incorporating a higher amount of
drug into the polymeric matrix, since the particle formation process is no longer random,
thereby allowing more control over drug encapsulation. The hydrogel template approach
does not require the application of excessive heat, mechanical force or any harsh treatment
conditions. It is a simple and fast process.
Early method development of the hydrogel template technology and initial study on the
effect of the particle size on drug release were discussed in previous publications (19, 20).
The main objective of the present study is to evaluate the hydrogel template method for
producing drug-loaded polymeric microparticles, with the goal of gaining a better
understanding of this method that will ultimately aid in method optimization. Three drugs
with different physicochemical properties were used as model compounds in this study. The
data obtained were compared and contrasted to microparticles prepared using the
conventional emulsion-based technique.
2. Materials and methods
2.1 Materials
Risperidone (RIS) and methylprednisolone acetate (MPA) were purchase from Sigma-
Aldrich (St. Louis, MO), paclitaxel (PTX) was supplied by Samyang Genex Corporation
(Republic of Korea). Poly(D,L-lactide-co-glycolide) (PLGA) 5050, 6535, 7525 and 8515
(corresponding to lactide:glycolide ratio of 50:50, 65:35, 75:25 and 85:15, respectively)
were purchased from Lactel (Pelham, AL). Poly(vinyl alcohol) (PVA, 87~89%, 96%,
98~99% and >99% hydrolyzed) of various typical molecular weight was purchased from
Sigma-Aldrich (St. Louis, MO). Benzyl alcohol (BA, analytical reagent grade), ethyl acetate
(EA, analytical reagent grade) and methylene chloride (DCM, analytical grade) were
purchased from VWR (Batavia, IL). All other chemicals or solvents were of reagent or
analytical grade and used as received without further purification.
2.2 Preparation of hydrogel templates
The basic approach to producing gelatin-based templates containing an array of cylindrical
posts with pre-determined diameters and heights was described before (19, 20). A similar
method was adopted to produce templates in this particular study with some modifications.
A silicon wafer master template was constructed by spin-coating with SU8 2010 photoresist
(Microchem, Cambridge, MA) at 3500 rpm for 30 s and baking, followed by ultraviolet
exposure radiation through a mask containing an array of circular patterns 10 μm in
diameter and subsequent developing and drying procedures according to manufacturer’s
instructions. The master template thus fabricated contained cylindrical wells 10 μm in
diameter and 10 μm in height. Next, the master template was coated with Sylgard 184
elastomer (Dow Corning, Elizabethtown, KY) consisting of approximately 50 g of pre-
polymer and 5 g curing agent in a flat-bottomed ceramic dish and cured at 70 °C for 2 hours.
The polydimethylsiloxane (PDMS) template was removed carefully from the silicon wafer
master template and flushed with ethanol, followed by drying with a nitrogen stream. This
intermediate PDMS template was used repeatedly in subsequent experiments to produce
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templates for making drug-loaded PLGA microparticles. PVA was dissolved at a
concentration of 4% (w/v) in a mixture of deionized water and ethanol (40:60 v/v) with
constant stirring and heating. The resulting solution was used to evenly coat the surface of
PDMS intermediate template. After solvent evaporation and template solidification, the
PVA template was gently peeled off the PDMS template and stored in a cool, dry place until
ready to use.
2.3 Preparation of polymer-drug solutions
RIS, MPA and PTX were chosen as model poorly water-soluble compounds in this study.
The properties of these compounds are presented in Table 1. The compounds were dissolved
with the selected type of PLGA polymer in a mixture of BA and EA or DCM. The types of
PLGA evaluated varied by lactide-to-glycolide ratio (L:G) and intrinsic viscosity (IV). Other
parameters that varied were the concentration of PLGA in solution, drug concentration and
ratio of BA to EA. A summary of the composition of drug solutions used in this study is
provided in Table 2.
2.4 Preparation of drug-loaded microparticles
Approximately 60 μl of polymer-drug solution was deposited along one edge of each PVA
template and spread evenly over its surface at room temperature. Excess solution was
carefully scraped away. This process was repeated several times with time in between to
allow template to dry. A batch of 20 filled PVA templates were dissolved in a beaker
containing 250 ml deionized water and gently stirred by magnetic stir bar at room
temperature. The suspension was transferred into conical tubes (45 ml) and centrifuged for 5
minutes (Eppendorf Centrifuge 5804, Eppendorf, Hauppauge, NY) at 5,000 rpm. The pellet
was re-suspended and washed at least 3 times, each time followed by centrifuging and re-
suspension. The pellet obtained upon final centrifugation was freeze-dried and stored at 4 °C
until further use.
2.5 Preparation of physical mixtures
Physical mixtures of drug and PLGA were prepared by weighing out each component and
gently mixing for at least ten minutes using mortar and pestle. Prior to mixing with drug,
PLGA was grounded into powder form using a ball mill. The amount of drug in the drug-
PLGA mixture was approximately 28%, 31% and 32% respectively for RIS, MPA and PTX.
These values were equal to the experimentally determined drug loading of microparticles.
2.6 Preparation of emulsions
A measured amount of RIS was dissolved in 5 ml of solvent consisting of 2.5 ml BA and 2.5
ml of EA along with 8515 PLGA. The concentration of polymer and drug (w/v) was 25 %
and 7.0 % respectively. The solution (organic phase) was emulsified with 250 ml of 0.5 %
(w/v) PVA solution in water (aqueous phase) at 5,000 rpm for 10 minutes. The resulting
emulsion was stirred at room temperature by magnetic stirrer for 3 hours to allow droplets to
harden by solvent extraction and evaporation. Thus-obtained microparticles were separated
by filtration and repeated washings followed by centrifugation at 5,000 rpm for 5 minutes to
collect. The collected microparticles were freeze-dried and stored at 4 °C until further use.
2.7 Characterization of microparticles
2.7.1 Particle size analysis—The mean size (volume average particle diameter) and size
distribution of drug-loaded PLGA microparticles were determined by a dynamic light
scattering analyzer (Microtrac S3500, Microtrac Inc., Largo, FL) equipped with appropriate
analysis software (Microtrac Flex Version 10.3.3). Size measurements were performed in
triplicate following suspension of microparticles in redistilled water at 25 °C. To prepare the
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samples for analysis, approximately 2 mg of freeze-dried microparticles were suspended in 5
ml of deionized water and vortexed for 5 minutes followed by sonication for 30 seconds.
2.7.2 Shape and morphology—The shape and surface morphology of microparticles
were characterized by fluorescence microscopy and scanning electron microscopy (SEM)
respectively. For fluorescence microscopy, a small amount of freeze-dried microparticles
were re-suspended in deionized water and deposited onto the surface of a clean glass slide
using a pipette. The sample was air-dried prior to viewing on the fluorescence microscope
(Olympus BX51, Olympus, Center Valley, PA). For surface morphology, FEI Nova™
NanoSEM (FEI, Hillsboro, OR) was used. Samples for characterization were prepared by
carefully depositing a small amount of freeze-dried microparticle powder onto the surface of
aluminum stubs and coating with platinum under vacuum conditions.
2.7.3 Physical stability—Solid form of drug, polymer, physical mixtures, microparticles
from emulsion and hydrogel template method were characterized with a powder X-ray
diffraction (PXRD) apparatus (Siemens Bruker D5000, Bruker AXS, Madison, WI) using
CuK radiation at 30 mA and 45 kV (scanning rate 0.4°/min), and diffraction angles (2θ) of
3–40°. Samples for PXRD were prepared by crushing a desired amount of drug, polymers,
physical mixture or microparticles with mortar and pestle before adding to the sample
holder. Excess powder sample was scraped away and the surface of the powder sample was
leveled with a glass slide. The procedure was repeated for samples that were stored for 1 – 2
months at 4 °C for physical stability assessment.
2.7.4 Drug loading—An accurately measured amount (5 mg) of freeze-dried drug-loaded
microparticles was dissolved in 1 ml of DCM and diluted with 9 ml of methanol. The
solution was vortexed to ensure thorough mixing. Following centrifugation for 5 minutes at
5,000 rpm, the supernatant containing dissolved drug was collected. The pellet containing
precipitated PLGA was washed with methanol several times and the washings were
combined with supernatant. This solution was rotary evaporated then re-dissolved by 10 ml
mobile phase for analysis by HPLC. The HPLC system (Agilent 1100 series, Agilent, Santa
Clara, CA) was equipped with autosampler, in-line degasser and UV absorbance detector.
The separation method for each drug is outlined below. Drug content was calculated using
the external standard method. Drug loading and encapsulation efficiency were calculated by
the following equations:
(1)
(2)
2.7.4.1 Risperidone: Separation was achieved using a X-Terra C-18 (250 mm × 4.6 mm)
analytical column from Waters (Milford, MA) at a flow rate of 1 ml/min, a detection
wavelength of 278 nm and injection volume of 65 μl. The mobile phase consists of
methanol: ammonium acetate (90:10 (v/v), pH adjusted to 7 with glacial acetic acid).
Samples and mobile phase were filtered through a 0.22 μm syringe filter and a 0.48 μm
membrane filter respectively prior to use.
2.7.4.2 Methylprednisolone acetate: Separation was achieved using a C-12 Sinergy MAX
RP (150 mm × 2.0 mm) analytical column (Chemtek Analytica, Italy) protected by a C-12
RP guard column at a flow rate of 0.2 ml/min, a detection wavelength of 278 nm and
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injection volume of 5 μl. The mobile phase consists of 50% water containing 0.01% formic
acid (A) and 50% acetonitrile (B). The A:B ratio was maintained for 6 minutes, then the
concentration of B was linearly increased to 100% B in 7 minutes, followed by another 15
minutes of isocratic elution (washing). The composition of the eluent was then restored to
the original condition of A:B = 50:50 (v/v) and re-equilibrated for 10 minutes before the
following injection. The column compartment was maintained at 30 °C.
2.7.4.3 Paclitaxel: Separation was achieved using a Phenomenex C-18 (250 mm × 4.6 mm)
analytical column (Torrance, CA) at a flow rate of 1 ml/min, a detection wavelength of 228
nm and injection volume of 20 μl. The mobile phase consists of water, acetonitrile and
methanol (40:30:30 v/v). Samples and mobile phase were filtered through a 0.22 μm syringe
filter and a 0.48 μm membrane filter respectively prior to use.
2.7.5 Thermal analysis—Differential scanning calorimetry (DSC) was carried out using
a DSC Q10 calorimeter (Mettler Toledo, Greifensee, Switzerland). Approximately 2 mg of
sample was weighed into aluminum pans and hermetically sealed. As a reference, an empty
aluminum pan was used. Samples were cooled down to −10 °C and then heated up to 180 °C
at a rate of 10 °C/min. For Tg determination, the data were analyzed using STAR software
(Mettler Toledo, Greifensee, Switzerland) and the midpoint of the corresponding glass
transition was evaluated. Tg was determined in triplicate for every sample.
2.8 In vitro release characterization
For RIS- and MPA-loaded microparticles, approximately 10 mg of microparticles was
accurately weighed into glass vials and re-suspended in 2 ml of PBS/Tween-20 (0.05%) (pH
7.4). The suspension was transferred carefully into a membrane cassette (Slide-A-Lyzer G2,
Thermo Scientific, Rockford, IL) with molecular weight cut off of 3,500. The cassettes were
incubated with 500 ml of PBS/Tween-20 (pH 7.4) at 37 °C in an orbital shaker set at 100
rpm throughout the duration of the release experiment. At predetermined intervals, 5 ml
samples were withdrawn from the release media and replaced with 5 ml of fresh buffer to
maintain sink conditions. The samples were collected in individual glass vials and stored at
4 °C till further analysis. Concentrations of RIS or MPA in the samples were determined by
HPLC analysis using the method outlined previously. For each formulation, the experiment
was performed in triplicate.
For PTX-loaded microparticles, due to extremely low aqueous solubility of the drug and
concentration detection limits of the HPLC method, the total volume of buffer used in
release studies was reduced. Approximately 2.5 mg of microparticles was accurately
weighed into glass vials and re-suspended in 1 ml of PBS/Tween 20 (pH 7.4). The
suspension was transferred carefully into a small-volume membrane cassette. The cassette
was incubated with 10 ml of PBS/Tween 20 at 37 °C in an orbital shaker set at 100 rpm
throughout the duration of the release experiment. At predetermined intervals, 5 ml samples
were withdrawn from the release media and replaced with 5 ml of fresh buffer. The samples
were collected in individual glass vials and stored at 4 °C till further analysis. Concentration
of PTX in the samples was determined by HPLC analysis using the method outlined
previously. The experiment was performed in triplicate.
2.9 Solubility determination
The saturation solubility of RIS, MPA and PTX were determined in BA, EA and DCM as
follows: an excess amount of each drug was transferred into glass vials containing 2 ml of a
specific solvent. The glass vials were equipped with screw-on caps to prevent solvent
evaporation. The vials containing the drug in the solvent were left on an orbital shaker at
room temperature under agitation. After 1 day, the solvent was removed and filtered through
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0.22 μm syringe filter. The concentration of the drug in solution was determined by HPLC
according to the method outlined in section 2.7.4.
2.10 Statistical analysis
Particle size measurements, drug loading and in vitro release experiments were performed in
triplicate. The results are expressed as mean ± standard deviation. Statistical differences
among groups were evaluated by unpaired t-test (between two groups) or one-way ANOVA
(between multiple groups) with Tukey’s multiple comparison test. When p<0.05, statistical
significance was considered to be achieved.
3. Results and Discussion
3.1 Development of the hydrogel template method
The ability to precisely control and manipulate microparticle geometry is highly valuable as
the shape and size of drug carriers have been shown to have an impact on biological
processes such as vasculature, circulation time, targeting efficiency, cellular uptake and
subsequent intracellular transport for therapeutic delivery (21). While the hydrogel template
approach produces microparticles of pre-defined size and shape, it requires further
development for practical applications, such as scale-up production of microparticles. In the
original method, gelatin was used as a hydrogel template material, because at a certain
concentration it possesses a mechanical strength sufficiently high to withstand physical
manipulation during template preparation and template filling. At the same time gelatin has
a gel-to-sol transition temperature mild enough not to adversely affect a broad range of
loaded drug. However, these gelatin templates cannot be stored for prolonged periods of
time without losing shape of the delicate patterns and encountering contamination issues,
which increases the difficulty associated with streamlining this process for scale-up
production. To overcome this issue, PVA was used in place of gelatin as a template material.
This water-soluble polymer has been used extensively as a stabilizer in nano- and micro-
particle preparations, has excellent film-forming properties due to its high tensile strength
and flexibility, and is resistant to commonly used organic solvents for filling templates (22,
23). In addition, PVA templates are advantageous compared with gelatin templates, since
the former can be stored for an extended period of time in a dry place without losing shape
of the patterns or encountering contamination issues. A large number of PVA templates can
be fabricated and stored until ready to be filled by polymer-drug solutions.
In the current study, different types of PVA, as defined by the percent hydrolyzed and
molecular weights, were explored for use as a template material for the hydrogel template
method. The type of PVA used in the final process was chosen based the duration of
template preparation time and stability of produced microparticles, as determined by
retention of designed particle shape. During this process, the PVA molecules with 87~89%
hydrolyzed, 96% hydrolyzed, 98~99% hydrolyzed and 99+% hydrolyzed were chosen for
evaluations because they represent the range of commercially available categories of PVA.
A mixture of water and ethanol was used to dissolve the PVA in preparation of template
solution because a solution based on water alone was found to shrink on the surface of
master PDMS template, which affected quality of templates produced. From preliminary
evaluations, 87~89% hydrolyzed PVA with average molecular weight of 146,000~186,000
Da (viscosity = 40~50 cP) was found to be the most suitable type of PVA with a preparation
time of 12 hours and good microparticle stability. Based on our previously defined selection
criteria, 98~99% and 99+% hydrolyzed PVA with average molecular weight of
146,000~186,000 Da were not selected due to long solubilization time (>3 days at 80 °C).
This is possibly due to high viscosity of the two polymers (55~65 cP), which is known to
increase difficulty with powder dispersal. This in turn leads to formation of lumps that
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cannot be readily broken down by agitation, a factor that directly results in long
solubilization times. When PVA with lower average molecular weight (13,000~23,000 Da,
31,000~50,000 Da) was used, solubilization time decreased dramatically to 5~6 hours at 80
°C due to the decrease in viscosity of polymer. However, from SEM images we can see that
microparticles produced from these templates showed shape changes from the designed
patterns on template (Figure 1). This result can be rationalized based on decreased ability of
PVA to stabilize microparticles. Therefore, in all subsequent studies, we chose 87~89%
hydrolyzed PVA with average molecular weight of 146,000~186,000 Da as the optimal
template polymer.
3.2 Effect of formulation and process parameters on microparticle size and morphology
Results from particle size characterization are presented in Table 2. With the exception of 3
out of the total of 16 formulations tested, the average particle size measured did not deviate
more than 10% (1 μm) from the target size of 10 μm predefined by the pattern on the
template. In addition, polydispersity indexes (PDI) for these groups were well below 0.5, a
fact that indicates low variance in particle size distribution. In contrast, commonly used
emulsion methods have been known to produce microparticles with very wide size
distribution. Keeping formulation parameters the same, we used a emulsion method to
prepare the microparticles. Although we were able to obtain microparticles with an average
particle size of 10.5 μm, the size distribution ranged from 2 to over 30 μm, and PDI was
significantly (p < 0.05) higher than the PDI of microparticles produced using the hydrogel
template method. Particle size is one of the most important characteristics of microparticle-
based drug delivery systems. It is a well-studied fact that particle size has important effects
on microparticle degradation rate, drug loading, and drug release properties (20). Therefore,
it is important to be able to control average particle size as well as size distribution of a
microparticle-based drug delivery system.
Average particle size and size distribution of microparticles were not dependent on the type
of PLGA (as defined by L:G ratio) or the drug type. The average particle size and PDI of
samples made from 5050, 6535, 7525 and 8515 PLGA of the same intrinsic viscosity did not
differ significantly (p<0.05) from each other. Similarly, the same conclusion can be reached
when comparing microparticles encapsulating RIS, MPA and PTX. A robust method is
advantageous because it broadens the scope of application, i.e., the method can be applied
towards a larger chemical design space. However, results from Table 2 also show that size
was dependent on intrinsic viscosity of polymer and polymer/drug concentration in solution.
As we can see from Table 2, PLGA with intrinsic viscosity of 0.95~1.20 dL/g, a polymer-
drug solution with 12.5% drug concentration and a solution with 6.2% PLGA concentration
produced microparticles with −19%, −26% and −23% size deviations from target 10 μm,
respectively. Observations from subsequent SEM images of these samples showed
fragmented, irregularly shaped and/or microparticles with cup-like structures containing
hollow centers (Figure 2). Possible causes include reduced ability of polymer-drug solution
to spread evenly on the surface of template (in the case of high viscosity PLGA or high drug
concentration) and inward collapse of microparticles with hollow centers (in the case of low
PLGA concentration). The formation of microparticles with cup-like structures when the
polymer concentration is low can be attributed to the capillary flow induced by non-uniform
evaporation of the polymer-drug solution during template filling process (24). This so-called
‘coffee ring effect’ has been shown to depend on factors such as solute concentration (25). A
possible method to be explored for overcoming this limitation in the hydrogel template
method is to increase the number of times template filling is carried out, such that the hollow
center is gradually filled.
The shape and morphology of microparticles prepared using the hydrogel template method
as characterized by fluorescent microscopy and SEM is presented in Figure 3. From Figure
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3-A showing microparticles prior to dissolving the PVA template in water we can see that
the microparticles showed good conformity to the shape designed by the hydrogel template.
However, the ability of microparticles to maintain original cylindrical shape as designed by
the template was found to depend on the intrinsic viscosity of PLGA. SEM images show
that PLGA with intrinsic viscosity of 0.55~0.75 dL/g was able to form cylindrical
microparticles with good conformity to the original template design after dissolving
templates in water and harvesting free microparticles (Figure 3 B–D). The same formulation
produced spherical microparticles by the emulsion method. In contrast, microparticles
prepared from PLGA with intrinsic viscosity of 0.24~0.54 dL/g was not able to maintain
their cylindrical shapes. SEM images show the formation of more rounded microparticles
that do not resemble that of the original template design (image not shown). This result can
be attributed to the fact that PLGA with lower intrinsic viscosity has shorter length polymer
chains and therefore more space between each polymer chain. When the templates were
dissolved to collect free microparticles, it is easier for water molecules to enter the
polymeric matrix and cause the microparticles to swell. This hypothesis is supported by the
slightly larger measured size of microparticles prepared using lower intrinsic viscosity
compared with those prepared using a higher intrinsic viscosity, even though the difference
was not statistically significant (p > 0.05). The cylindrical shape microparticles may have
slightly different drug release properties from the spherical microparticles, but it would not
really matter as long as the drug release rate can be controlled.
Another possible factor that may have led to changes in microparticle shape is the glass
transition temperature (Tg) of polymer. Studies have shown that during microparticle
formation the structure of polymeric microparticles is strongly affected by the Tg of the
polymer, which marks the change between the rigid, glassy and the more flexible, rubbery
state (26). It can be assumed that the shape and morphology of the microparticle is only
formed in the rubbery state, providing that Tg is below the processing temperature.
Moreover, Tg of polymer has been shown to decrease with increasing levels of residual
solvent in the microparticle system (27). In our case the shape difference between
microparticles prepared using 0.24~0.54 dL/g PLGA and 0.55~0.75 dL/g PLGA was not
thought to be caused by differences in Tg of PLGA. The Tg of the two types of PLGA
measured by DSC were 48.8 °C and 51.2 °C, respectively, which were within the range
specified by the manufacturer of PLGA. The Tg of PLGA is expected to depreciate the most
from the measured Tg immediately after template filling and prior to air-drying. However,
the extent of Tg change is expected to be similar for both types of PLGA regardless of
intrinsic viscosity, as has been shown in other studies that Tg depression as a result of
residual solvent is not dependent on PLGA molecular weight, which has direct correlations
with intrinsic viscosity (27). Therefore, we do not expect significant differences between Tg
of 0.24~0.54 dL/g and 0.55~0.75 dL/g PLGA during production and processing of
microparticles using the hydrogel template method. The measured Tg of microparticles after
collecting and drying was approximately 45±1 °C. The slight depression in Tg before and
after processing may be due to low levels of residual solvent in the microparticles. The
microparticles were freeze-dried before use, and thus, the residual solvent, if it exists, may
be very low. The potential effect of the residual solvent on drug release, however, needs to
be studied in detail in the future.
In general, the hydrogel template method enabled us to prepare microparticles with
relatively smooth, non-porous surfaces. The presence of pores on microparticle surfaces has
been shown to increase the rate of drug release from microparticles by acting as transport
pathways for drug and water molecules (28). Furthermore, pores at the surface of
microparticles have been shown to correlate with initial burst release of drugs from
microparticle drug delivery systems, and those with more pores tend to show a more rapid
drug release (29). Therefore, from a controlled drug delivery perspective, it is often
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desirable to control pore size if not eliminate the presence of pores entirely. The surface
characteristic of microparticles is strongly dependent on the solvent removal process, i.e.,
solvent evaporation and extraction kinetics (3). In the hydrogel template method, solvent
removal occurs primarily through solvent evaporation during the template filling and drying
stage, with limited supplementary solvent extraction when the template is exposed to water
and microparticles become briefly suspended in the aqueous phase. The ability of the
hydrogel template method to prepare microparticles with relatively smooth, non-porous
surfaces is most likely due to slow solvent evaporation in the preparation process as well as
minimized contact with water during the particle formation process. To control the rate of
solvent evaporation, we used a binary co-solvent system consisting of BA (boiling point:
205 °C) and EA (boiling point: 77.1 °C). These solvents were selected based on the criteria
that the solvents should be able to dissolve both the polymer and the drug at the
concentrations used while having no detrimental effect on the integrity of template material.
Slow solidification allows microparticles to remain soft for a longer period, which leads to
particle compaction within the template. To further investigate, DCM (boiling point: 39.6
°C) instead of EA was used in combination with BA to prepare the polymer-drug solution.
This binary co-solvent system is expected to have a lower boiling point than the BA and EA
system, which promotes more rapid solvent evaporation. SEM study of the microparticles
prepared using this new solvent system showed large pores forming on the surface of
microparticles (Figure 4), which is consistent with the prediction based on faster solvent
evaporation caused by boiling point depression of the new solvent system.
3.3 Effect of formulation and process parameters on drug loading and encapsulation
efficiency
Using the hydrogel template method, we successfully encapsulated model drugs, RIS, MPA
and PTX, into a PLGA matrix. X-ray diffractograms of drug-loaded microparticles prepared
by the hydrogel template method in comparison with drug alone, polymer alone or physical
mixtures are shown in Figure 5. The X-ray diffractogram suggests that the process of
encapsulating the drug in microparticles using the hydrogel template method resulted in the
loss of crystallinity of the drug. The emulsion method also produced microparticles that
encapsulated drug in amorphous form. For RIS, dominant peaks at 2θ angles between 13°
and 15° and between 18° and 22° were observed for pure drug. The polymer PLGA is
predominantly amorphous as indicated by the slight shift above baseline and lack of any
dominant peaks. The peaks characteristic of RIS at 2xetas; angles of 14° and 21.5° were still
observable for the physical mixture of RIS and PLGA at a concentration of 10% (w/w) RIS
in the physical mixture. However, the peaks were lost in the X-ray diffractogram of
microparticles prepared by the hydrogel template method, indicating amorphization of RIS.
The same general trend can be observed for model drugs MPA and PTX (Figure 5-B and 4-
C), indicating that all three model drugs were encapsulated in the amorphous form within
the PLGA matrix. Conversion of the drug from crystalline into an amorphous form is also
commonly observed in other microparticle preparation methods such as spray-drying and
emulsion-based methods. Potential advantages are enhanced dissolution and saturation
solubility of the drug, properties that are particularly important for delivery of poorly water
soluble drugs such as the model drugs studied here. However, stability is a major concern
since amorphous active pharmaceutical ingredients may undergo recrystallization during
further processing and/or storage (30). The physical state of the encapsulated drug after
storage at 4 °C for over 2 months was characterized by XRD experiments and comparing
collected diffractograms with X-ray diffractograms obtained immediately after collecting
and drying the microparticles. The results show overlap of the diffractogram patterns, which
suggests that devitrification did not take place (Figure 5-A).
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A comparison of drug loading of RIS is presented in Figure 6 As was expected, the drug
loading was found to depend on drug, polymer and solvent interactions. Figure 6-A shows
that RIS drug loading increased when lactide content of PLGA increased. Drug loadings
were 7.09±2.6% and 26.2±5.4%, respectively, for 5050 PLGA and 8515 PLGA,
corresponding to the encapsulation efficiencies of 20.3% and 74.6%, respectively.
Increasing the lactide content of PLGA most likely enhanced hydrophobic interactions
between polymer and RIS, thus, resulting in higher drug loading and encapsulation
efficiency. This is predicted by the interaction parameter, which can be calculated based on
the following equation:
Where χ is the interaction parameter, δd and δp are solubility parameters for drug and
polymer, respectively, and Vd is the molar volume of drug. With the δd value of 17.5 for
RIS, 21.7 for 8515 PLGA and 22.3 for 5050 PLGA (31), the calculated χ values for
RIS-8515 PLGA and RIS-5050PLGA are approximately 2.27 and 2.97, respectively. The
lower value of RIS-8515 PLGA indicates better polymer-drug compatibility. Increasing
PLGA concentration in the polymer-drug solution resulted in higher drug loading as well as
encapsulation efficiency (Figure 6-B). At a polymer concentration of 25.0% in the polymer-
drug solution, the drug loading achieved was 28.4±2.7%. This trend has also been
demonstrated for emulsion-based methods (32) and can be attributed to increased viscosity
of the solution such that drug diffusion through the polymer matrix is limited (33).
Furthermore it has been shown that a low polymer concentration may result in polymer
microparticles with drug crystals penetrating the polymer shell, which leads to drug loss
during washing and further processing (34). Increasing the concentration of drug in
polymer-drug solution did not result in higher drug loading or encapsulation efficiency
beyond a RIS concentration of 7.0%. As we can see in Figure 6-C, from a drug
concentration of 4.3% to 7.0% a corresponding increase in drug loading from 19.3±3.5% to
26.2±2.1% was seen, but further increasing the drug concentration to 12.5% did not lead to a
significant change in drug loading. There were no significant differences between
encapsulation efficiency at 4.3% and 7.0% drug concentration (77.2% and 74.6%,
respectively), but encapsulation efficiency at 12.5% drug concentration was significantly
lower at 49.8%. This observation again emphasizes the importance of polymer-drug
compatibility in amount of drug loading and encapsulation efficiency.
Drug loading and encapsulation efficiency were also found to be affected by the solvent
ratio (Figure 6-D). In the current study we found that increasing volume ratio of EA
increased drug loading and encapsulation efficiency, though the increase was not significant
beyond BA:EA volume ratio of 50:50. The higher drug loading and encapsulation efficiency
seen when BA:EA volume ratio decreased is likely due to less surface associated drug.
When solubility experiments were carried out, we found that the solubility of RIS is much
lower in EA than in BA. Typically, migration of the drug during drying and storage steps
can lead to heterogeneous distribution of drug molecules within the polymeric matrix (35). It
is reasonable to assume that as BA is removed from the microparticles, it carries with it a
certain amount of drug which may easily be lost to the aqueous environment or during
washing steps. Lowering the BA:EA ratio decreases the amount of RIS able to diffuse along
with BA to the external surface of microparticles, thereby increasing the drug loading and
encapsulation efficiency. In addition, EA evaporates faster than BA at room temperature due
to a much lower boiling point. The rate of solvent removal affects microparticle
solidification; that is, fast solidification (fast solvent removal) may impede drug diffusion to
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the surface by fast formation of a dense polymer matrix. This may reduce drug diffusion to
the surface and increase drug loading and encapsulation efficiency.
It is interesting to note that faster solvent removal does not automatically equate higher drug
loading and encapsulation efficiency. For RIS, using EA-BA solvent system resulted in
higher drug loading and encapsulation efficiency than DCM-BA solvent system (Figure 7).
Due to the lower boiling point of DCM compared to EA, it is expected to be removed at a
more rapid rate compared to EA. In this case, solvent removal was so rapid that it facilitated
the formation of numerous surface pores, which was confirmed by SEM imaging. The
presence of surface pores may have increased drug loss to the aqueous environment during
washing.
Drug loading and encapsulation efficiencies are also dependent on the properties of the
encapsulated drug. Using 8515 PLGA at 25.0% w/v, we achieved 31.5±3.9% and
32.2±4.1% drug loading for MPA and PTX respectively, corresponding to encapsulation
efficiencies of 90.0% and 92.0% PTX, respectively. These values were significantly
(p<0.05) higher than that of RIS (Figure 7). One possible explanation is that MPA and PTX
have higher compatibility with the polymer 8515 PLGA, which led to enhanced interaction
between polymer and drug. Using the Hildebrand-modified approach, the interaction
parameter χ can be calculated based on the following equation:
where δd and δp are partial solubility parameters due to dispersion, polarity and hydrogel
bonding forces for drug and polymer respectively. The values for partial solubility
parameters were obtained from literature (31). Based on the above equation, the interaction
parameters between 8515 PLGA and RIS, MPA and PTX are 2.74, 0.309 and 0.811,
respectively. Clearly MPA and PTX have higher compatibility with 8515 PLGA compared
to RIS. Another possible cause for the difference in drug loading and encapsulation
efficiency can be attributed to the difference in solubilities of the drugs in the solvents. Drug
with higher solubility in a particular organic solvent (e.g., RIS in BA versus MPA in BA)
may diffuse towards the surface of the microparticles in greater amount than one with a
lower solubility in the said solvent. A third factor that may contribute towards the drug
loading trends we see here is the aqueous solubility of the drug. While PTX has a higher
solubility in BA compared to RIS, the loss of surface associated PTX from microparticles
may have been hindered by the extremely low aqueous solubility of the drug compared to
RIS. The amount of drug loading is therefore determined by a combination of factors that
involve drug-polymer compatibility, drug-solvent interaction and drug properties.
3.4 Effect of formulation and process parameters on in vitro release
The in vitro release profiles of RIS formulations are presented in Figure 8. Previously, we
showed that the following formulation parameters produced fragmented microparticles or
microparticles irregular in shape: low IV PLGA (IV = 0.26~0.54 dL/g), high IV PLGA (IV
= 0.95~1.2 dL/g), low PLGA concentration in organic solution (6.2% w/v) and increased
drug content (12.5% w/v). Because size and shape of the microparticles greatly affect drug
release (36), these formulations were eliminated from direct comparison in in vitro studies
with microparticles that were able to maintain original template size and shape.
Among the formulation and process-related parameters studied, initial burst release and
subsequent release of RIS from microparticles produced by the hydrogel template method
were found to be influenced by L:G ratio of PLGA. Figure 8-A compares release profiles of
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RIS-loaded microparticles made using 5050, 6535, 7525 and 8515 PLGA. Initial burst
release percentages were 22.1±2.3%, 18.5±2.0%, 12.8±1.5% and 7.2±2.8% for the four
formulations, respectively. The limited amount of burst release seen in microparticles made
from 8515 PLGA is particularly remarkable considering the relatively high drug loading we
were able to obtain from this formulation. In many cases, burst release increases with
increasing drug loading (37, 38) due to the elution of surface associated drugs and a high
concentration gradient between microparticle and surrounding release medium (23). As
previously discussed, diffusion of drug to the surface of the microparticles in the hydrogel
template method is limited by drug solubility in the solvent used and drug-polymer
interaction. Increasing the lactide content presumably contributed to the latter by enhancing
hydrophobic interaction between drug and polymer. In addition, decreasing the
hydrophilicity of PLGA inhibited water uptake from the release medium, which in turn
resulted in lower initial burst release (39). The L:G ratio of PLGA also exerted an effect on
subsequent release. As is shown in Figure 8-A, the onset of more rapid release was slower
for PLGA with higher lactide content. The rate of drug release over the next 21 days
decreased with increasing L:G ratio. Microparticles made from 5050 PLGA showed a
cumulative 77.6±3.1% release while those produced using 8515 PLGA showed 61.5±2.2%
cumulative release by the end of the three week period. Following initial burst release, drug
is mainly released when the polymer matrix degrades and the drug diffuses from the eroded
matrix (40). It is well-established that the rate of PLGA degradation decreases with
increasing the lactide content due to the more hydrophobic nature of PLGA as lactide
content increases (41). Therefore, it is expected that the rate of drug released over time will
be on the order of 8515 < 7525 < 6535 < 5050 PLGA. This result is in accordance with trend
observed in studies using conventional preparation methods (42).
Figure 8-B compares in vitro release of RIS microparticles made using different BA and EA
volume ratios or DCM instead of EA. As was expected, the initial release did not change
significantly when BA content decreased from 50:50 to 30:70 (p > 0.05). When BA was
increased to 60:40, the initial burst release increased significantly to 13.4±2.3% (p < 0.05).
As we have previously explained, the increase in BA content likely resulted in more surface-
associated RIS. In comparison, RIS microparticles made using BA and DCM showed a
significantly higher initial burst release of 26.3±3.8%. The large initial release can be
attributed to both surface associated drug as well as the porous structure of microparticles as
seen by SEM images. The porous structure facilitated diffusion of water into the
microparticle as well as drug out from the microparticle. Compared to the formulation
prepared from BA and EA, the formulation prepared using BA and DCM saw a higher
overall rate of release, with 67.0±3.0 % drug release over the three-week period compared to
61.5±2.2% drug release in BA-EA formulation. The higher cumulative release rate can be
attributed to the formation of less dense microparticles due to the faster removal of DCM
compared to EA. Typically, a more slow solvent removal process provides more time for
microparticle to condense and form denser polymeric matrices. This may be a barrier to
water diffusion, which may partially slow down the rate of polymer degradation and
subsequent drug release.
The in vitro release profiles for RIS, MPA and PTX were compared in Figure 9.
Interestingly, MPA microparticles showed very low levels of burst release (<1 %) and a
distinct lag phase of approximately 10 days. Over the following 4 days, MPA was rapidly
released and over 80% of drug content was released by the 16th day. The suppression of
burst release in MPA-loaded microparticles may be attributed to differences in drug
distribution in the polymeric matrix compared to RIS-loaded microparticles. As discussed in
previous section, MPA is less soluble than RIS in both BA and DCM. During the air-drying
process, it is less likely to migrate towards the surface of microparticles than RIS. On the
other hand, PTX-loaded microparticles showed increased levels of burst release compared to
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RIS microparticles with almost no lag phase before steady release. This is in accordance
with our previous observation that higher solubility of drug in organic solvent leads to
higher initial burst release due to the migration of drug molecules to surface of
microparticles. It is noted that the MPA was released at an accelerated rate after Day 10 of
the secondary release phase. This may be due to multiple reasons, and one possible
explanation is the drug release through the microchannels formed by the diffusing water. At
this stage, the drug release depends on the interactions among the drug, PLGA, and water.
Like MPA-loaded microparticles, more than 80 % of total drug loaded was released by day
16.
3.5 Comparison of the hydrogel template method and emulsion method
As previously discussed, the emulsion-based method is one of the most commonly used
ways to prepare drug-loaded polymeric microparticles. However, three major limitations of
the emulsion method are wide particle size distribution, use of heat (during solvent
extraction and evaporation process) and relatively low drug loading. From the particle size
data we obtained in this study, we found that microparticles produced using the emulsion
method showed a polydispersity of 0.39 which is significantly higher than the polydispersity
value of 0.15 for the microparticles prepared using the hydrogel template method. The
microparticles were mostly spherical in shape with smooth surfaces and few pores. In
commercial preparation of microparticles using emulsion-based methods, a secondary
processing step is almost always required to further reduce particle size distribution. This
increases time and cost of production, and is less desirable than a single process that allows
us to achieve the desirable target size range.
Similar to the hydrogel template method, drug encapsulated within microparticles made by
the emulsion method were amorphous in form as characterized by XRD. Drug loading and
encapsulation efficiency were 28.3±0.7% and 80.8% respectively, values that were
comparable to drug loading and encapsulation efficiency of the hydrogel template
microparticles prepared using the same formulation (8515 PLGA, 12.5% w/v PLGA, 7.0%
w/v drug, BA:EA=50:50 v/v). In vitro release profiles of RIS-loaded microparticles prepared
using the two different methods are presented in Figure 10. Microparticles prepared from the
hydrogel template and emulsion method showed initial burst release of 7.2±1.1% and
10.1±3.0%, respectively. The burst release from hydrogel template method was slightly
lower compared to microparticle prepared from the emulsion method. Both types of
microparticles displayed a period of slow release until day 10, followed by more rapid
release. The cumulative release over a period of three weeks was also comparable, reaching
61±2.8% for the hydrogel template and 63.2±8.0% for emulsion. These results demonstrate
that microparticles prepared using the hydrogel template method were at least comparable in
in vitro performance to microparticles prepared from the conventional emulsion method.
The major advantages associated with using the hydrogel template over emulsion seem to be
particle size homogeneity, which is reflected in the smaller variations in subsequent in vitro
release profiles. Furthermore, the hydrogel template method allows additional manipulation
of PLGA composition and use of different types of polymers.
4. Conclusion
Drug-loaded PLGA microparticles prepared using the hydrogel template method were
characterized and evaluated using three poorly-water soluble, model drugs: RIS, MPA and
PTX. The microparticles were characterized based on size, shape, morphology, drug
loading, encapsulation efficiency as well as in vitro release. Among the formulation and
process-related parameters studied, it was found that the ability of produced microparticles
to retain the designed shape was dependent on molecular weight of template material as well
as viscosity of filling solution. When these two parameters were optimized, the
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microparticles formed showed good conformity to the original template design for a wide
range of formulation conditions, which demonstrates the robustness as well as the broad
applicability of the hydrogel template method. In addition, the microparticles produced
showed small size distribution, which provided an advantage compared to the conventional
emulsion-based method. Drug loading and encapsulation efficiency of microparticles
prepared using the hydrogel template method were found to increase with lactide content of
PLGA, concentration of PLGA in solution and decreasing BA content. The trends observed
were expected and can be explained using well-established microencapsulation principles.
Using this method, we were able to suppress initial burst release of two model compounds to
below 10 % and extend the release for at least 21 days. The low initial burst release is
particularly remarkable considering the relatively high drug loading we were able to achieve
for these microparticles. The hydrogel template method has been demonstrated to produce
microparticles that perform at least comparably in vitro to microparticles from the emulsion-
based method. Efforts are underway to characterize and understand how these microparticles
will perform in vivo. Applications of homogeneous micdroparticles are likely to extend to
coating of drug to various biomedical devices, such as drug-eluting vascular stents and
angioplasty balloons (43)
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Figure 1.
Scanning electron microscope images of microparticles prepared using 87~89% hydrolyzed
PVA templates of various average molecular weights: (A) 13,000~23,000 Da; (B)
31,000~50,000 Da; and (C) 146,000~186,000 Da.
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Figure 2.
Scanning electron microscope images of RIS-containing microparticles prepared using
12.5% PLGA with intrinsic viscosity of 0.95~1.20 dL/g (A), PLGA-RIS (12.5%–12.5%)
solution (B), and PLGA-RIS (6.2%–7.0%) solution (C).
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Figure 3.
Fluorescent (A and B) and scanning electron microscope (C and D) images of microparticles
prior to (A) dissolving PVA templates and after collecting and drying (B–D).
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Figure 4.
SEM image showing large pores formed on the surface of microparticles prepared by using
a co-solvent containing DCM.
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Figure 5.
X-ray diffractograms comparing pure drug and encapsulated form of RIS (A), MPA (B), and
PTX (C).
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Figure 6.
Comparison of drug loading trends for RIS formulations A) effect of PLGA type based on
L:G ratio; B) effect of PLGA concentration; C) effect of drug concentration; D) effect of
solvent ratio. *: p<0.05; **: p<0.001
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Figure 7.
Comparison of drug loading and encapsulation efficiency of model compounds. MPA
microparticles were prepared from BA and DCM solvent mix (v/v=50:50) due to low
solubility in EA
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Figure 8.
Comparison of RIS drug release from formulation in phosphate buffer (pH 7.4, 37 °C) A)
comparison by PLGA type (L:G); B) comparison by different solvent combinations
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Figure 9.
Comparison of release profiles of RIS, MPA and PTX from 8515 PLGA microparticles.
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Figure 10.
Comparison of release profiles of RIS-loaded microparticles prepared using hydrogel
template and emulsion methods
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Table 1
Physicochemical properties of model drugs risperidone, methylprednisolone acetate and paclitaxel
Compound
RIS MPA PTX
Molecular Structure
Molecular Weight (g/mol) 410.5 416.5 853.9
Aqueous Solubility (μg/ml)* 211 120 0.3
LogP* 2.5 1.5 3.0
pKa* 8.24, 3.11 12.58 10.36
*Value obtained from DrugBank, based on experimental properties
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